Jonathan Schwartz

Company: Rocket Pharmaceuticals Ltd.

Job title: Chief Medical Officer

Seminars:

Key Learnings from a Cardiac Targeted Program 9:30 am

• Exploring the evidence for limited turnover of cardiomyocytes in children and adults • Reviewing 2-3 year gene expression follow-up in Phase 1 Danon disease AAV9 trial • Navigating a long term follow up of adult patients with Danon DiseaseRead more

day: Day Two AM